BIOPHARMA CREDIT PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.878 USD | +0.23% |
|
+0.23% | +4.52% |
| Apr. 24 | BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals | MT |
| Apr. 24 | BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals | AN |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,463 | 1,401 | 1,368 | 1,330 | 1,253 | 1,094 |
| Enterprise Value (EV) 1 | 1,100 | 1,105 | 1,175 | 1,235 | 1,133 | 959.2 |
| P/E ratio | 15 x | 11.5 x | 15.4 x | 15.7 x | 7.11 x | 10.1 x |
| Yield | 6.19% | 6.86% | 7.03% | 7.23% | 7.37% | 8.33% |
| Capitalization / Revenue | 15 x | 9.29 x | 12.4 x | 12.8 x | 5.74 x | 8.06 x |
| EV / Revenue | 11.3 x | 7.32 x | 10.7 x | 11.9 x | 5.19 x | 7.07 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | 33.9 x | 11 x | 20.8 x | 30.7 x | 9.13 x | 16.9 x |
| FCF Yield | 2.95% | 9.12% | 4.82% | 3.26% | 11% | 5.93% |
| Price to Book | 1.06 x | 1 x | 0.99 x | 0.98 x | 0.94 x | 0.82 x |
| Nbr of stocks (in thousands) | 1,373,932 | 1,373,932 | 1,373,872 | 1,373,872 | 1,319,179 | 1,302,679 |
| Reference price 2 | 1.065 | 1.020 | 0.9960 | 0.9680 | 0.9500 | 0.8400 |
| Announcement Date | 3/4/19 | 3/18/20 | 3/25/21 | 3/21/22 | 3/30/23 | 3/27/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 97.32 | 150.9 | 110 | 103.9 | 218.2 | 135.7 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | 74.08 | 122.3 | 89.15 | 84.98 | 182.3 | 108.5 |
| Operating Margin | 76.12% | 81.07% | 81.03% | 81.8% | 83.58% | 79.9% |
| Earnings before Tax (EBT) 1 | 70.15 | 122.3 | 89.14 | 84.96 | 182.3 | 108.4 |
| Net income 1 | 70.15 | 122.3 | 89.14 | 84.96 | 182.3 | 108.4 |
| Net margin | 72.08% | 81.06% | 81.02% | 81.79% | 83.56% | 79.9% |
| EPS 2 | 0.0709 | 0.0890 | 0.0649 | 0.0618 | 0.1337 | 0.0828 |
| Free Cash Flow 1 | 32.43 | 100.8 | 56.6 | 40.26 | 124.1 | 56.88 |
| FCF margin | 33.32% | 66.76% | 51.45% | 38.75% | 56.88% | 41.9% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | 46.23% | 82.36% | 63.5% | 47.38% | 68.07% | 52.45% |
| Dividend per Share 2 | 0.0659 | 0.0700 | 0.0700 | 0.0700 | 0.0700 | 0.0700 |
| Announcement Date | 3/4/19 | 3/18/20 | 3/25/21 | 3/21/22 | 3/30/23 | 3/27/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 364 | 297 | 193 | 94.7 | 121 | 135 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 32.4 | 101 | 56.6 | 40.3 | 124 | 56.9 |
| ROE (net income / shareholders' equity) | 6.09% | 8.79% | 6.41% | 6.2% | 13.5% | 8.1% |
| ROA (Net income/ Total Assets) | 3.99% | 5.42% | 3.96% | 3.85% | 8.33% | 4.98% |
| Assets 1 | 1,756 | 2,258 | 2,254 | 2,207 | 2,187 | 2,176 |
| Book Value Per Share 2 | 1.000 | 1.020 | 1.000 | 0.9900 | 1.010 | 1.030 |
| Cash Flow per Share 2 | 0.2600 | 0.2200 | 0.1400 | 0.0700 | 0.0900 | 0.1000 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/4/19 | 3/18/20 | 3/25/21 | 3/21/22 | 3/30/23 | 3/27/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.878
Average target price
-
| 1st Jan change | Capi. | |
|---|---|---|
| +4.52% | 1.08B | |
| +3.74% | 12.61B | |
| +5.50% | 9.01B | |
| -3.20% | 5.41B | |
| +2.44% | 5.25B | |
| +5.63% | 5.19B | |
| +14.36% | 4.48B | |
| +16.67% | 4.44B | |
| +1.53% | 4B | |
| +1.56% | 3.75B |
- Stock Market
- Equities
- BPCP Stock
- Financials BioPharma Credit PLC
